Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
Brandon Michael Henry, Chief Executive and Medical Officer at Aurelix Bio, shared a post on Linkedin about a recent article he and his colleague co-authored, published in Seminars in Thrombosis and Hemostasis, adding:
“Complement activation after AAV gene therapy is complex to interpret.
Early post-dose changes in platelets, C3/C4, or soluble C5b-9 do not automatically mean toxicity. In many cases, they may reflect expected pharmacodynamic engagement of innate immunity after vector exposure.
The clinical challenge is recognizing when that biology remains self-limited – and when it begins to evolve toward sustained complement amplification, endothelial injury, and thrombotic microangiopathy.
Our article in Seminars in Thrombosis and Hemostasis focuses on that interpretive boundary.
We provide a practical framework for integrating complement biomarkers with hematologic and renal markers, with emphasis on assay limitations, timing, trajectory, and clinical context.
The main point: gene therapy safety monitoring should not only ask whether complement activation is present.
It should ask what pattern it is following, whether it is resolving or escalating, and whether the broader clinical picture suggests expected biology or early vascular injury.”
Title: Laboratory Monitoring of Complement Activation in Gene Therapy: Analytical Pitfalls and Clinical Interpretation
Authors: Brandon M Henry, Melvin Y Rincon, Giuseppe Lippi, Zoltán Prohászka, Stefanie Benoit

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice